Figure 2
From: Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD
Assessment of riboswitch dosing kinetics in HEK293T cells. Normalized GFP fluorescence and representative GFP (inducible) and mCherry (non-inducible) images at varying concentrations of activating ligand for (A) K19, (B) L2Bulge9, (C) L2Bulge18tc, (D) GuaM8HDV and (E) TC45. Dynamic range is represented as fold-change. n = 3, **p > 0.01, ***p > 0.001, ****p > 0.001, One-Way ANOVA with Tukey’s post-hoc test. For each group, respective fluorescent channels were recorded with constant exposure and gain; scale bars = 50 μM.
